Exploring genes within the glutathione peroxidase family as potential predictors of prognosis in papillary renal cell carcinoma

IF 1.4 4区 医学 Q4 ONCOLOGY
Chenlu Li, Tao Zhang, Mi Yan, Yan Chen, Ruchao Nan, Jun Chen, Xiaoyu Wang
{"title":"Exploring genes within the glutathione peroxidase family as potential predictors of prognosis in papillary renal cell carcinoma","authors":"Chenlu Li, Tao Zhang, Mi Yan, Yan Chen, Ruchao Nan, Jun Chen, Xiaoyu Wang","doi":"10.1515/oncologie-2024-0056","DOIUrl":null,"url":null,"abstract":"\n \n \n This research aims to explore the relationship between glutathione peroxidase (GPX) expression variations in papillary renal cell carcinoma (pRCC) and patient survival, while also developing and evaluating a customized survival prediction model based on GPX.\n \n \n \n The transcriptomic dataset, including clinical parameters and GPX expression levels, is sourced from The Cancer Genome Atlas (TCGA) database, comprising 290 individuals diagnosed with pRCC. We utilized a univariate Cox regression model to select differentially expressed genes. Subsequently, we calculated risk scores through the least absolute shrinkage and selection operator (LASSO) regression. Based on the median risk score, patients were categorized into high and low-risk groups, establishing a prognostic risk model. Following this, the relationship between the risk model and the survival of pRCC patients was revealed through Kaplan–Meier survival curve analysis. The sensitivity and specificity of the predictive model were evaluated using receiver operating characteristic (ROC) curve analysis. Furthermore, chemotherapy drug sensitivity analysis was conducted on patients in the high and low-risk groups.\n \n \n \n A risk-scoring model was built by selecting GPX7 and GPX8. Compared to the low-risk group, individuals in the high-risk category showed significantly reduced overall survival rates (p=0.018). Additionally, validation results demonstrated the model’s good predictive accuracy.\n \n \n \n The risk-scoring model constructed based on GPX family genes provides an innovative biomarker for forecasting the prognosis of pRCC and serves as a reference for individualized therapy in pRCC.\n","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/oncologie-2024-0056","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This research aims to explore the relationship between glutathione peroxidase (GPX) expression variations in papillary renal cell carcinoma (pRCC) and patient survival, while also developing and evaluating a customized survival prediction model based on GPX. The transcriptomic dataset, including clinical parameters and GPX expression levels, is sourced from The Cancer Genome Atlas (TCGA) database, comprising 290 individuals diagnosed with pRCC. We utilized a univariate Cox regression model to select differentially expressed genes. Subsequently, we calculated risk scores through the least absolute shrinkage and selection operator (LASSO) regression. Based on the median risk score, patients were categorized into high and low-risk groups, establishing a prognostic risk model. Following this, the relationship between the risk model and the survival of pRCC patients was revealed through Kaplan–Meier survival curve analysis. The sensitivity and specificity of the predictive model were evaluated using receiver operating characteristic (ROC) curve analysis. Furthermore, chemotherapy drug sensitivity analysis was conducted on patients in the high and low-risk groups. A risk-scoring model was built by selecting GPX7 and GPX8. Compared to the low-risk group, individuals in the high-risk category showed significantly reduced overall survival rates (p=0.018). Additionally, validation results demonstrated the model’s good predictive accuracy. The risk-scoring model constructed based on GPX family genes provides an innovative biomarker for forecasting the prognosis of pRCC and serves as a reference for individualized therapy in pRCC.
探索谷胱甘肽过氧化物酶家族中的基因作为乳头状肾细胞癌预后的潜在预测因子
本研究旨在探索乳头状肾细胞癌(pRCC)中谷胱甘肽过氧化物酶(GPX)表达变化与患者生存之间的关系,同时开发和评估基于GPX的定制化生存预测模型。 包括临床参数和 GPX 表达水平在内的转录组数据集来自癌症基因组图谱(TCGA)数据库,其中包括 290 名确诊为 pRCC 的患者。我们利用单变量 Cox 回归模型来选择差异表达基因。随后,我们通过最小绝对收缩和选择算子(LASSO)回归法计算风险评分。根据中位风险评分,将患者分为高风险组和低风险组,建立预后风险模型。随后,通过 Kaplan-Meier 生存曲线分析揭示了风险模型与 pRCC 患者生存率之间的关系。预测模型的灵敏度和特异性通过接收者操作特征曲线(ROC)分析进行评估。此外,还对高风险组和低风险组患者进行了化疗药物敏感性分析。 通过选择 GPX7 和 GPX8,建立了一个风险评分模型。与低风险组相比,高风险组患者的总生存率明显降低(P=0.018)。此外,验证结果表明该模型具有良好的预测准确性。 基于GPX家族基因构建的风险评分模型为预测pRCC的预后提供了一种创新的生物标志物,并为pRCC的个体化治疗提供了参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncologie
Oncologie 医学-肿瘤学
CiteScore
1.30
自引率
11.10%
发文量
32
审稿时长
6-12 weeks
期刊介绍: Oncologie is aimed to the publication of high quality original research articles, review papers, case report, etc. with an active interest in vivo or vitro study of cancer biology. Study relating to the pathology, diagnosis, and advanced treatment of all types of cancers, as well as research from any of the disciplines related to this field of interest. The journal has English and French bilingual publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信